How Botox Helps with Migraine Headaches: Treating the Glabella Area and Masseter

Chronic migraine is one of the most debilitating neurological conditions in the world. According to the World Health Organization, migraine ranks as the second leading cause of years lived with disability globally, affecting an estimated 1.1 billion people. In the United States alone, approximately 39 million individuals live with migraine, and roughly 4 million of those experience chronic migraine — defined as 15 or more headache days per month, with at least eight of those meeting the clinical criteria for migraine.

For decades, patients with chronic migraine relied on a patchwork of preventive medications — beta-blockers, anticonvulsants, antidepressants — many of which were developed for entirely different conditions and carried significant side effects. Then, in 2010, the U.S. Food and Drug Administration approved onabotulinumtoxinA (marketed as Botox by Allergan) specifically for the prevention of chronic migraine in adults. It was a landmark moment, not only because it gave patients a targeted, well-tolerated treatment option, but because it fundamentally changed our understanding of how migraine pain works at the neuromuscular level.

What makes Botox particularly effective for migraine is its ability to target specific anatomical regions that serve as trigger zones for headache pain. Among the most clinically significant of these zones are the glabella — the area between the eyebrows — and the masseter, the powerful jaw muscle responsible for chewing and clenching. Together, these two regions represent a dual approach to migraine prevention that addresses both the neurological and musculoskeletal drivers of chronic headache.

In this article, we explore the science behind Botox for migraine, examine why the glabella and masseter are such critical treatment areas, and walk through what patients can expect from the procedure — from the first consultation to long-term results.

Before diving into the treatment itself, it is important to understand what distinguishes chronic migraine from the more common episodic variety. The International Headache Society defines chronic migraine as a condition in which a patient experiences headaches on 15 or more days per month for at least three consecutive months, with at least eight of those days meeting the full diagnostic criteria for migraine — meaning they involve moderate to severe pain, unilateral location, pulsating quality, nausea, or sensitivity to light and sound.

Episodic migraine, by contrast, involves fewer than 15 headache days per month. While episodic migraine can certainly be disabling, chronic migraine represents a fundamentally different clinical challenge. Patients with chronic migraine often develop central sensitization, a state in which the nervous system becomes increasingly reactive to pain signals. This means that even minor stimuli — a change in weather, a skipped meal, a stressful conversation — can trigger a full migraine episode.

The impact on quality of life is profound. Studies consistently show that chronic migraine sufferers are significantly more likely to experience depression, anxiety, sleep disorders, and reduced workplace productivity compared to those with episodic migraine. Many patients cycle through multiple preventive medications without finding adequate relief, a situation known as treatment-refractory chronic migraine. It was precisely this population that the PREEMPT clinical trials — the studies that led to Botox's FDA approval — were designed to help.

When most people hear "Botox," they think of cosmetic wrinkle reduction. And indeed, onabotulinumtoxinA works by temporarily blocking the release of acetylcholine at the neuromuscular junction, preventing targeted muscles from contracting. But the mechanism by which Botox prevents migraine is fundamentally different from — and more sophisticated than — simple muscle relaxation.

Research over the past two decades has revealed that Botox acts on the sensory nervous system, not just the motor system. When injected into the tissues surrounding peripheral nerve endings, onabotulinumtoxinA inhibits the release of key pain-signaling molecules, most notably calcitonin gene-related peptide (CGRP) and substance P. These neuropeptides are central players in the migraine cascade — they trigger vasodilation, neurogenic inflammation, and the transmission of pain signals from the peripheral nervous system to the brain.

By blocking the release of CGRP and substance P at the nerve terminal level, Botox effectively interrupts the migraine before it can begin. This is a preventive mechanism, not an acute one — Botox does not stop a migraine that is already in progress, but rather reduces the frequency and severity of future episodes by calming the hyperexcitable nerve endings that initiate the pain cascade.

The landmark PREEMPT clinical trials (Phase III Research Evaluating Migraine Prophylaxis Therapy) demonstrated this convincingly. Conducted across 122 study sites in North America and Europe, the PREEMPT 1 and PREEMPT 2 trials enrolled over 1,300 patients with chronic migraine. Patients who received Botox injections every 12 weeks experienced a statistically significant reduction in headache days, migraine days, and the use of acute headache medications compared to placebo. The results were consistent across both trials and were maintained over multiple treatment cycles.

Importantly, the trials also established the injection paradigm that is still used today: a standardized protocol of 31 injection sites across seven head and neck muscle groups, using a total dose of 155 to 195 units of onabotulinumtoxinA.

The glabella is the smooth area of skin between the eyebrows, directly above the nose. Beneath the skin of the glabella lie two key muscle groups: the corrugator supercilii muscles (responsible for drawing the eyebrows together to create vertical frown lines) and the procerus muscle (responsible for pulling the skin between the eyebrows downward, creating horizontal wrinkles across the bridge of the nose).

For migraine patients, the glabellar region is far more than a cosmetic concern. It is one of the most densely innervated areas of the face, with rich concentrations of branches from the supratrochlear and supraorbital nerves — both divisions of the trigeminal nerve, which is the primary sensory nerve of the face and a central player in migraine pathophysiology.

Clinical observations have long noted that many migraine patients report pain that originates in or radiates through the glabellar region. The phenomenon of "glabellar trigger points" — specific areas of muscle tension or nerve sensitivity that can initiate or exacerbate a migraine episode — has been documented in multiple studies. In a widely cited 2000 study published in Plastic and Reconstructive Surgery, researchers found that surgical removal of the corrugator supercilii muscles in patients with frontal migraines led to complete or significant migraine improvement in 80% of cases, providing early evidence that this anatomical region plays a direct role in migraine generation.

The standard PREEMPT injection protocol includes five injection sites in the glabellar region: one in the procerus muscle and two in each corrugator supercilii muscle, with 5 units of onabotulinumtoxinA per site for a total of 25 units. The injections are placed superficially, just deep enough to reach the muscle belly, using a fine-gauge needle.

By relaxing the corrugator and procerus muscles and — more importantly — by blocking the release of CGRP from the trigeminal nerve terminals in this region, glabellar Botox injections reduce the frequency of migraine episodes that originate from or pass through this critical trigger zone. Many patients report that the glabellar injections are the single most impactful component of their migraine Botox protocol.

The masseter is one of the strongest muscles in the human body, responsible for elevating the mandible during chewing and clenching. It runs from the zygomatic arch (cheekbone) to the angle and ramus of the mandible (lower jaw). While the masseter is not part of the standard 31-site PREEMPT protocol for chronic migraine, it has emerged as an increasingly important treatment target for patients whose migraines are driven by or exacerbated by temporomandibular joint (TMJ) dysfunction and bruxism (teeth grinding and jaw clenching).

The connection between the masseter and migraine is rooted in the anatomy of the trigeminal nerve. The same nerve that innervates the glabellar muscles also provides motor and sensory innervation to the muscles of mastication, including the masseter. When the masseter is chronically hypertonic — whether due to stress-related clenching, sleep bruxism, or TMJ dysfunction — it generates a sustained barrage of sensory input through the trigeminal nerve that can trigger or perpetuate the central sensitization associated with chronic migraine.

Multiple studies have demonstrated the co-occurrence of TMJ disorders and chronic migraine. A 2018 systematic review published in the Journal of Oral Rehabilitation found that patients with TMJ disorders were 2.5 to 8 times more likely to suffer from chronic headaches compared to those without TMJ pathology. The relationship appears to be bidirectional: TMJ dysfunction exacerbates migraine, and chronic migraine increases the likelihood of jaw clenching and bruxism, creating a self-reinforcing cycle.

Botox injections into the masseter — typically 15 to 25 units per side, placed at two to three points in the bulk of the muscle — address both the muscular and neurological components of this cycle. The injections reduce the force of involuntary clenching and grinding, which in turn reduces the sensory overload on the trigeminal nerve. Patients often report improvement not only in headache frequency but also in jaw pain, ear pain, and the characteristic "tight band" sensation around the temples that accompanies masseter-driven tension headaches.

For patients who present with both chronic migraine and evidence of masseter hyperactivity — such as visibly enlarged masseter muscles, worn tooth enamel, or a history of TMJ clicking and locking — the addition of masseter injections to the standard PREEMPT protocol can provide a meaningful incremental benefit. Some practitioners now refer to this as the "PREEMPT-plus" approach.

The rationale for treating both the glabella and the masseter in the same session is grounded in the concept of convergent trigeminal pathways. The trigeminal nerve has three main divisions — ophthalmic (V1), maxillary (V2), and mandibular (V3). The glabellar region falls primarily under V1, while the masseter is innervated by V3. By targeting both areas, the clinician addresses pain-generating input from two distinct trigeminal territories, reducing the total volume of nociceptive signaling that reaches the trigeminal nucleus caudalis in the brainstem — the relay station where peripheral pain signals are processed and transmitted to higher cortical centers.

In clinical practice, the combined glabella-masseter approach has shown particular promise for patients who describe their migraines as involving both frontal and temporal pain, or who report a pattern of headaches that seem to begin with jaw tension and escalate into a full migraine. These patients often have a mixed presentation that does not respond fully to either upper-face or lower-face treatment alone.

The full PREEMPT protocol already includes injection sites in the frontalis, corrugator, procerus, temporalis, occipitalis, cervical paraspinal, and trapezius muscles — a total of 31 sites using 155 units. For patients with significant masseter involvement, the treating physician may add an additional 30 to 50 units (15-25 per side) to the masseter, bringing the total to approximately 185 to 205 units per session. This "follow-the-pain" philosophy, in which additional units are directed to areas of maximal tenderness or trigger point activity, is explicitly endorsed in the PREEMPT protocol guidelines.

It is worth noting that treating both the glabella and the masseter in a single session does not significantly increase the risk of adverse effects. The total dose remains well within the established safety profile of onabotulinumtoxinA, and the anatomical distance between the two injection sites minimizes the risk of unintended diffusion.

The Botox migraine treatment process typically begins with a comprehensive consultation. During this visit, the treating physician will review the patient's headache history, including frequency, duration, location, associated symptoms, and prior treatments. A thorough examination of the head and neck muscles is performed to identify areas of tenderness, trigger points, and muscle hypertrophy — particularly in the glabellar and masseter regions.

Patients must meet the International Headache Society criteria for chronic migraine (15+ headache days per month for at least three months) to be eligible for Botox treatment under the FDA-approved indication. Many insurance providers also require documentation of failure with at least two prior preventive medication classes before authorizing Botox for migraine.

The procedure itself is straightforward and typically takes 15 to 20 minutes. The physician uses a fine 30- or 32-gauge needle to deliver small volumes (0.1 mL per site) of reconstituted onabotulinumtoxinA into the predetermined injection sites. Most patients describe the sensation as a mild pinch or sting, similar to a mosquito bite. Topical numbing cream or ice can be applied beforehand, though most patients tolerate the procedure well without anesthesia.

For the glabellar region, the physician targets three to five sites in the procerus and corrugator muscles, injecting 5 units per site. For the masseter, two to three sites per side are typical, with 15 to 25 units distributed across the muscle belly. The entire treatment — including the remaining PREEMPT sites in the temporalis, occipitalis, and trapezius — involves approximately 31 to 39 injection sites.

Post-treatment care is minimal. Patients are advised to remain upright for four hours after the procedure, avoid rubbing or massaging the treated areas for 24 hours, and refrain from strenuous exercise on the day of treatment. These precautions help prevent unintended migration of the toxin to adjacent muscles.

The onset of migraine-preventive benefit is gradual. Most patients begin to notice a reduction in headache frequency two to four weeks after the first treatment, with the maximum effect typically reached at six to eight weeks. The effects of a single treatment session last approximately 10 to 12 weeks, which is why the standard retreatment interval is every 12 weeks (four times per year).

The clinical evidence supporting Botox for chronic migraine is robust and continues to grow. The pooled results from the PREEMPT 1 and PREEMPT 2 trials demonstrated that patients receiving Botox experienced an average reduction of 8 to 9 headache days per month compared to a 6 to 7 day reduction with placebo — a statistically significant difference that translates to a clinically meaningful improvement in quality of life.

Across both trials, approximately 65 to 70 percent of patients achieved at least a 50 percent reduction in headache days by the third treatment cycle. This response rate is notable because the PREEMPT study population consisted of patients with severe, treatment-refractory chronic migraine — many of whom had failed multiple prior preventive therapies.

One of the most important findings from the PREEMPT data is the cumulative benefit of repeated treatment cycles. Patients who continued Botox treatment over three to five cycles showed progressively greater reductions in headache days, suggesting that the prophylactic effect builds over time. This is consistent with the theory that Botox gradually reverses the central sensitization that underlies chronic migraine by reducing the volume of peripheral pain signaling over successive treatment periods.

Real-world observational studies have largely confirmed these findings. A 2020 analysis of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study found that patients who received Botox for chronic migraine reported significant improvements in headache-related disability, work productivity, and overall quality of life. Similar results have been reported in European and Asian cohorts, suggesting that the benefit is consistent across populations.

It is important to set realistic expectations, however. Botox is not a cure for migraine — it is a preventive treatment that reduces frequency and severity. Some patients respond dramatically, going from 20+ headache days per month to fewer than five, while others experience more modest improvement. Patients who have co-occurring conditions such as medication overuse headache, depression, or sleep disorders may require a multimodal approach that addresses these contributing factors alongside Botox treatment.

OnabotulinumtoxinA has an extensive safety record spanning more than three decades of clinical use across multiple indications. In the context of chronic migraine treatment, the PREEMPT trials and subsequent real-world studies have consistently demonstrated a favorable safety profile.

The most commonly reported side effects are mild and transient:

• Injection site pain or tenderness — typically resolves within 24 to 48 hours
• Mild headache — paradoxically, some patients experience a temporary increase in headache on the day of injection
• Neck stiffness — related to the cervical paraspinal and trapezius injection sites
• Brow ptosis (slight drooping of the eyebrow) — occurs in approximately 2 to 4 percent of patients receiving glabellar injections, typically resolves within 2 to 4 weeks

Rare but documented side effects include localized muscle weakness, difficulty swallowing (when posterior neck muscles are treated), and allergic reactions at the injection site. Systemic spread of toxin effects (botulism-like symptoms) is a theoretical risk but has not been reported at the doses used for migraine treatment.

Contraindications include known hypersensitivity to botulinum toxin, infection at the proposed injection sites, and pregnancy or breastfeeding. Patients with neuromuscular disorders such as myasthenia gravis or Lambert-Eaton syndrome should not receive Botox due to the risk of exacerbating muscle weakness.

Because Botox is FDA-approved specifically for chronic migraine, many insurance plans — including most major commercial insurers and Medicare — provide coverage for the treatment. However, obtaining authorization typically requires meeting specific criteria:

• A confirmed diagnosis of chronic migraine (15+ headache days per month for at least 3 months)
• Documentation of failure or intolerance with at least two classes of preventive medication (e.g., beta-blockers, topiramate, amitriptyline, or a CGRP monoclonal antibody)
• Treatment administered by a qualified healthcare provider in a medical setting

The out-of-pocket cost of Botox for migraine, without insurance, ranges from approximately $1,200 to $2,500 per treatment session in the United States, depending on the total dose used and the provider's geographic location. For European patients — particularly in the DACH region (Germany, Austria, Switzerland) — treatment costs vary by country and whether the treatment is covered under statutory or private health insurance. In Germany, onabotulinumtoxinA for chronic migraine is covered by most Gesetzliche Krankenversicherung (GKV) plans when the clinical criteria are met.

Allergan (now part of AbbVie) offers a patient assistance program called Botox Savings Program that can reduce co-pays for commercially insured patients. Patients should discuss all financial options with their provider before beginning treatment.

For patients undergoing regular Botox treatments for migraine, maintaining an accurate and detailed treatment record is essential. Knowing exactly what was injected, where it was injected, in what dose, and from which product lot can make the difference between a seamless continuity of care and a frustrating gap in medical history — particularly when switching providers or seeking a second opinion.

Aesthetic Pass is a digital treatment passport designed specifically for aesthetic and therapeutic injection patients. With Aesthetic Pass, every treatment session is recorded with full clinical detail: the product used (including lot number for supply chain verification), the anatomical injection sites, the number of units per site, and before-and-after documentation. For migraine patients receiving Botox, this means having a complete, portable history of every treatment cycle — accessible from your phone, shareable with any provider via a secure QR code.

The app's treatment timeline makes it easy to track your 12-week retreatment schedule, monitor your response over successive cycles, and share a verified treatment history with new providers or insurance companies. For patients managing a complex condition like chronic migraine, this level of documentation is not just convenient — it is clinically valuable.